248 related articles for article (PubMed ID: 8640718)
1. Long-term follow-up of minimal residual disease in childhood acute lymphoblastic leukemia patients by polymerase chain reaction analysis of multiple clone-specific or malignancy-specific gene markers.
Kuang S; Gu L; Dong S; Cao Q; Xu C; Huang W; Su XY; Huang QH; Xie JX; Chen SJ; Chen Z
Cancer Genet Cytogenet; 1996 Jun; 88(2):110-7. PubMed ID: 8640718
[TBL] [Abstract][Full Text] [Related]
2. Analysis of Ig and T-cell receptor genes in 40 childhood acute lymphoblastic leukemias at diagnosis and subsequent relapse: implications for the detection of minimal residual disease by polymerase chain reaction analysis.
Beishuizen A; Verhoeven MA; van Wering ER; Hählen K; Hooijkaas H; van Dongen JJ
Blood; 1994 Apr; 83(8):2238-47. PubMed ID: 8161789
[TBL] [Abstract][Full Text] [Related]
3. PCR-heteroduplex analysis of TCR gamma, delta and TAL-1 deletions in T-acute lymphoblastic leukemias: implications in the detection of minimal residual disease.
Nirmala K; Rajalekshmy KR; Raman SG; Shanta V; Rajkumar T
Leuk Res; 2002 Apr; 26(4):335-43. PubMed ID: 11839375
[TBL] [Abstract][Full Text] [Related]
4. A polymerase chain reaction study of the stability of Ig heavy-chain and T-cell receptor delta gene rearrangements between presentation and relapse of childhood B-lineage acute lymphoblastic leukemia.
Steward CG; Goulden NJ; Katz F; Baines D; Martin PG; Langlands K; Potter MN; Chessells JM; Oakhill A
Blood; 1994 Mar; 83(5):1355-62. PubMed ID: 8118037
[TBL] [Abstract][Full Text] [Related]
5. Long-term follow-up of residual disease in acute lymphoblastic leukemia patients in complete remission using clonogeneic IgH probes and the polymerase chain reaction.
Nizet Y; Van Daele S; Lewalle P; Vaerman JL; Philippe M; Vermylen C; Cornu G; Ferrant A; Michaux JL; Martiat P
Blood; 1993 Sep; 82(5):1618-25. PubMed ID: 8364210
[TBL] [Abstract][Full Text] [Related]
6. Detectable molecular residual disease at the beginning of maintenance therapy indicates poor outcome in children with T-cell acute lymphoblastic leukemia.
Dibenedetto SP; Lo Nigro L; Mayer SP; Rovera G; Schilirò G
Blood; 1997 Aug; 90(3):1226-32. PubMed ID: 9242556
[TBL] [Abstract][Full Text] [Related]
7. Age-related patterns of immunoglobulin and T-cell receptor gene rearrangements in precursor-B-ALL: implications for detection of minimal residual disease.
van der Velden VH; Szczepanski T; Wijkhuijs JM; Hart PG; Hoogeveen PG; Hop WC; van Wering ER; van Dongen JJ
Leukemia; 2003 Sep; 17(9):1834-44. PubMed ID: 12970784
[TBL] [Abstract][Full Text] [Related]
8. Prospective monitoring of minimal residual disease during the course of chemotherapy in patients with acute lymphoblastic leukemia, and detection of contaminating tumor cells in peripheral blood stem cells for autotransplantation.
Seriu T; Yokota S; Nakao M; Misawa S; Takaue Y; Koizumi S; Kawai S; Fujimoto T
Leukemia; 1995 Apr; 9(4):615-23. PubMed ID: 7723394
[TBL] [Abstract][Full Text] [Related]
9. Assessment of clonal evolution at Ig/TCR loci in acute lymphoblastic leukaemia by single-strand conformation polymorphism studies and highly resolutive PCR derived methods: implication for a general strategy of minimal residual disease detection.
Baruchel A; Cayuela JM; MacIntyre E; Berger R; Sigaux F
Br J Haematol; 1995 May; 90(1):85-93. PubMed ID: 7786801
[TBL] [Abstract][Full Text] [Related]
10. Detection of minimal residual disease in childhood acute lymphoblastic leukemia after termination of therapy.
Wu NH; Lu SG; Zhu P; Peng YY
Pediatr Hematol Oncol; 1996; 13(3):257-63. PubMed ID: 8735342
[TBL] [Abstract][Full Text] [Related]
11. Kinetics of minimal residual disease during induction/consolidation therapy in standard-risk adult B-lineage acute lymphoblastic leukemia.
Scholten C; Födinger M; Mitterbauer M; Laczika K; Mitterbauer G; Haas OA; Knöbl P; Schwarzinger I; Thalhammer R; Purtscher B
Ann Hematol; 1995 Oct; 71(4):155-60. PubMed ID: 7578520
[TBL] [Abstract][Full Text] [Related]
12. Residual disease detection in multiple follow-up samples in children with acute lymphoblastic leukemia.
Kitchingman GR
Leukemia; 1994 Mar; 8(3):395-401. PubMed ID: 8127144
[TBL] [Abstract][Full Text] [Related]
13. Characterization of clonal immunoglobulin heavy chain and I cell receptor gamma gene rearrangements during progression of childhood acute lymphoblastic leukemia.
Marshall GM; Kwan E; Haber M; Brisco MJ; Sykes PJ; Morley AA; Toogood I; Waters K; Tauro G; Ekert H
Leukemia; 1995 Nov; 9(11):1847-50. PubMed ID: 7475273
[TBL] [Abstract][Full Text] [Related]
14. Prospective monitoring and quantitation of residual blasts in childhood acute lymphoblastic leukemia by polymerase chain reaction study of delta and gamma T-cell receptor genes.
Cavé H; Guidal C; Rohrlich P; Delfau MH; Broyart A; Lescoeur B; Rahimy C; Fenneteau O; Monplaisir N; d'Auriol L
Blood; 1994 Apr; 83(7):1892-902. PubMed ID: 8142656
[TBL] [Abstract][Full Text] [Related]
15. Prolonged persistence of PCR-detectable minimal residual disease after diagnosis or first relapse predicts poor outcome in childhood B-precursor acute lymphoblastic leukemia.
Steenbergen EJ; Verhagen OJ; van Leeuwen EF; van den Berg H; Behrendt H; Slater RM; von dem Borne AE; van der Schoot CE
Leukemia; 1995 Oct; 9(10):1726-34. PubMed ID: 7564517
[TBL] [Abstract][Full Text] [Related]
16. Characterisation of non-concordance in the T-cell receptor gamma chain genes at presentation and clinical relapse in acute lymphoblastic leukemia.
Taylor JJ; Rowe D; Kylefjord H; Chessells J; Katz F; Proctor SJ; Middleton PG
Leukemia; 1994 Jan; 8(1):60-6. PubMed ID: 8289500
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group.
Cavé H; van der Werff ten Bosch J; Suciu S; Guidal C; Waterkeyn C; Otten J; Bakkus M; Thielemans K; Grandchamp B; Vilmer E
N Engl J Med; 1998 Aug; 339(9):591-8. PubMed ID: 9718378
[TBL] [Abstract][Full Text] [Related]
18. PCR detection of clonal IgH and TCR gene rearrangements at the end of induction as a non-remission criterion in children with ALL: comparison with standard morphologic analysis and risk group classification.
Scrideli CA; Queiroz RG; Bernardes JE; Valera ET; Tone LG
Med Pediatr Oncol; 2003 Jul; 41(1):10-6. PubMed ID: 12764736
[TBL] [Abstract][Full Text] [Related]
19. Sequential monitoring of minimal residual disease in acute lymphoblastic leukemia: 7-year experience in a pediatric hematology/oncology unit.
Katsibardi K; Moschovi MA; Braoudaki M; Papadhimitriou SI; Papathanasiou C; Tzortzatou-Stathopoulou F
Leuk Lymphoma; 2010 May; 51(5):846-52. PubMed ID: 20350276
[TBL] [Abstract][Full Text] [Related]
20. Minimal residual disease after intensive induction therapy in childhood acute lymphoblastic leukemia predicts outcome.
Gruhn B; Hongeng S; Yi H; Hancock ML; Rubnitz JE; Neale GA; Kitchingman GR
Leukemia; 1998 May; 12(5):675-81. PubMed ID: 9593264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
